Page 14
( Table 4 ). It is important these tests stress they are for inherited cancers and not epigenetic changes that lead to most malignancies .
Table 4 : Inherited cancer tests Test
Developer
Cellmax-Dna Genetic Cancer Risk Test |
CellMax Life Inc . |
Color Test |
Color Health Inc . |
Multiple |
Invitae Corp . |
Empower Hereditary Cancer Test |
Natera Inc . |
Gene2me Plus |
Eone-Diagnomics Genome Center Co . Ltd . |
Genetype Multi Test |
Genetic Technologies Ltd . |
Myrisk Hereditary Cancer Test |
Myriad Genetics Inc . |
Ovanext + Colonext |
Konica Minolta Inc . |
Source : goetzpartners Research , BioCentury Inc .
Liquid biopsy market for pan cancer detection shows potential The liquid biopsy market for pan-cancer screening is dominated by a few players . The CtDNA-targeting Galleri from Grail is being validified with large patient cohorts across the UK and the USA . In Asia , Burning Rock Biotech screens for methylated DNA to backtrack to the tumour location and Exact Sciences in Europe use a similar mechanism . One question that remains to be answered is whether these multi-cancer early detection tests can assess the aggressiveness of the cancers they detect to make a meaningful difference in patients ’ prognoses , rather than over-diagnosing indolent cancers . Increasingly these companies are using a variety of methods of liquid biopsy to gain as much information as possible and a combination of CtDNA or CtRNA , EV and CtCells may be the future for these tests . It would allow the company to diagnose early cancer , but importantly have a risk stratification for how aggressive they are . These are not widely used yet with revenues limited as the tests are still in larger trials .
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .